10 Years of Data Reveals Excellent, Sustained Local Control with Minimal Side Effects for Medically Inoperable, Early Stage Lung Cancer Patients Who Received High-Dose Rate Stereotactic Body Radiotherapy (SBRT)
American Society for Radiation Oncology (ASTRO)Analysis of data from an institutional patient registry on stereotactic body radiotherapy (SBRT) indicates excellent long-term, local control, 79 percent of tumors, for medically inoperable, early stage lung cancer patients treated with SBRT from 2003 to 2012, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.